Vertex Pharmaceuticals Incorporated

ISIN US92532F1003 Symbol VRTX Industry Biotechnology Sector Healthcare
Vertex Pharmaceuticals Price
191.9USD 2.36%
1y Low: 202.6
1y High: 306.1
1y Low: 202.6
1y High: 306.1
Vertex Pharmaceuticals Analyst Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
vrtx.com
Market Cap
55.2 B USD
Dividend Yield
Performance 1y
36.47 %
PER
20.6

Vertex Pharmaceuticals Stock Chart

Vertex Pharmaceuticals Dividend Chart

Vertex Pharmaceuticals Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Vertex Pharmaceuticals Performance

1 Week
1 Month
10.17 %
6 Months
19.34 %
Year to Date
18.27 %
1 Year
36.47 %
5 Years
134.9 %

Vertex Pharmaceuticals Revenue, EBIT, and Income

Vertex Pharmaceuticals Margins

Vertex Pharmaceuticals Shares Outstanding

Useful Links

Search Twitter: $VRTX, #VRTX

Vertex Pharmaceuticals Company Info

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Headquarter

50 Northern Avenue, 02210 Boston, MA, USA

Vertex Pharmaceuticals Price to Earnings Ratio (PE Ratio): 20.6

The current Price to Earnings Ratio of Vertex Pharmaceuticals is 20.6.
The PE Ratio is calcluated by dividing the current Vertex Pharmaceuticals share price (191.9 USD) by the earnings per share (10.3).

Vertex Pharmaceuticals Market Cap: 55.2 B USD

The current market cap of Vertex Pharmaceuticals is 55.2 B USD.

Vertex Pharmaceuticals Stock Price: 191.9 USD

The current stock price of Vertex Pharmaceuticals is 191.9 USD.

Vertex Pharmaceuticals ISIN: US92532F1003

The ISIN (International Securities Identification Number) of Vertex Pharmaceuticals is US92532F1003.

Vertex Pharmaceuticals Ticker Symbol: VRTX

The ticker symbol of Vertex Pharmaceuticals is VRTX.

Vertex Pharmaceuticals Address

The address of the Vertex Pharmaceuticals HQ is 50 Northern Avenue, 02210 Boston, MA, USA.